Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee

NCT02697773 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

698

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoarthritis, Knee
Osteoarthritis, Hip

Interventions

OTHER: Placebo
BIOLOGICAL: Tanezumab 2.5 mg
BIOLOGICAL: Tanezumab 2.5mg/5mg

Sponsor

Pfizer